- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The study by Wada et al. (N=7, 2-15 years) shows that the pharmacokinetic parameters of granisetron in children with oncological disorders have a pronounced inter-individual variation. The following pharmacokinetic parameters were found:
| Craft 1995 | Wada 2001 | |||
| Age | 2-6 years | 7-11 years | 12-16 years | 2-15 years |
| Cmax (mg/l) | 59.9 ± 57.3 | 41.5 ± 18.3 | 45.2 ± 23.7 | 60.1 ± 26.6 |
| t½ (h) | 8.93 ± 7.14 | 6.22 ± 3.32 | 5.82 ± 6.31 | 20.9 ± 20.8 |
| Cl (ml/h/kg) | 193 ± 146 | 352 ± 341 | 360 ± 271 | 121 ± 76 |
| Vd (l/kg) | 1.44 ± 0.487 | 1.81 ± 0.712 | 1.32 ± 0.514 | 2.57 ± 1.87 |
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Prevention and treatment of post-operative nausea and vomiting |
|---|
|
| Nausea and vomiting in chemotherapy |
|---|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No data is known about dosage adjustments for renal function disorders in children. The manufacturer states that no special precautions are required in patients with renal insufficiency.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Headaches, lower abdominal pain, obstipation, diarrhoea, sleepiness and insomnia.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Given that granisetron can reduce intestinal motility, patients with symptoms of acute or subacute intestinal obstruction after granisetron is administered should be monitored closely. There are studies in which a small, clinically non-relevant, QT interval extension has been observed in children. For the sake of safety, caution should be exercised in children with risk factors for QT extension.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Serotonin (5HT3) antagonists | ||
|---|---|---|
| A04AA01 | ||
| A04AA05 | ||
| Other antiemetics | ||
|---|---|---|
| A04AD12 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Aksoylar S, et al, Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy, Pediatr Hematol Oncol, 2001, 18, 397-406
- Berrak SG, et al, A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy, Support Care Cancer, 2007, 15, 1163-8
- Cieslak GD, et al, The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis, Anesthesiology, 1996, 85, 1076-85
- Fujii Y, et al, Treatment of vomiting after paediatric strabismus surgery with granisetron, droperidol, and metoclopramide, Ophthalmologica., 2002, 216, 359-62
- Fujii Y, et al, Preoperative oral granisetron for the prevention of vomiting following paediatric surgery, Paediatr Anaesth, 2002, 12, 267-71
- Fujii Y, et al, Prevention of postoperative vomiting with granisetron in paediatric patients with and without a history of motion sickness, Paediatr Anaesth., 1999, 9, 527-30
- Fujii Y, et al, Granisetron reduces post-operative vomiting in children: a dose-ranging study., Eur J Anaesthesiol, 1999, 16, 62-5
- Hählen K, et al, A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children., J Pediatr, 1995, 126, 309-13
- Komada Y, et al, A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy, Eur J Cancer, 1999, 35, 1095-101
- Wada I, et al, Pharmacokinetics of granisetron in adults and children with malignant diseases, Biol Pharm Bull, 2001, 24, 432-5
- Mylan BV, SmPC Granisetron (RVG 30753/4) , www.cbg-meb.nl
- EMA, Rapporteurs Public Assessment Report for paediatric data in EU Worksharing procedure.Kytril/granisetron. UK/W/0014/pdWS/001, Geraadpleegd 1 juli 2013
- Roche Nederland BV, SmPC Kytril IV (RVG 20958), www.cbg-meb.nl
- Siddique R, et al. , Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia, Mymensingh Med J. , 2011, Oct;20(4), 680-8.
- Gombar S et al., Superior anti-emetic efficacy of granisetron-dexamethasone combination in children undergoing middle ear surgery, Acta Anaesthesiologica Scandinavica , 2007, 51, 621-4
- Munro HM et al., Oral granisetron for strabismus surgery in children, Can J Anaesth, 1999, 46(1), 45-8
- Craft AW et al. , Granisetron as antiemetic therapy in children with cancer., Med Pediatr Oncol., 1995 , Jul;25(1), 28-32
- Riad W et al. , Combination therapy in the prevention of PONV after strabismus surgery in children: granisetron, ondansetron, midazolam with dexamethasone. , Middle East J Anaesthesiol., 2009 , Oct;20(3), 431-6
- Sinha R et al. , Granisetron versus granisetron-dexamethasone for prevention of postoperative nausea and vomiting in pediatric strabismus surgery: a randomized double-blind trial., Anesthesiol Res Pract., 2016, 4281719
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
